Pipeline news

• Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

  12 December 2018

  

  Marinus Pharmaceuticals, Inc.  (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of  $3.75  per share. The total public offering size is expected to be  $45.0 million , before deducting the underwriting discounts and commissions and other offering expenses payable by the Company. 

• Marinus Pharmaceuticals Announces Public Offering of Common Stock

  11 December 2018

  

  Marinus Pharmaceuticals, Inc.  (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering.  All of the shares in the offering are to be sold by Marinus.   Jefferies LLC  and  Leerink Partners LLC  are acting as joint bookrunning managers for the offering. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock. 

• Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression

  10 December 2018

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the Magnolia Study) and oral (the Amaryllis Study) in women with postpartum depression (PPD). Based on these results, the Company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens.

• Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients

  04 December 2018

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that ganaxolone data from its Phase 2 clinical trial in pediatric genetic epilepsies, CDKL5 Deficiency Disorder (CDD) and PCDH19-related pediatric epilepsy (PCDH19 epilepsy) were presented at the  American Epilepsy Society  ( AES ) Annual Meeting in  New Orleans  on  December 2  and 3, 2018.

• Atea Pharmaceuticals to Present Positive Clinical Data with At-527 for the Treatment of Chronic Hepatitis C in Patients with Cirrhosis at The Liver Meeting ® 2018

  09 November 2018

  

  Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today announced it will present positive data from its recently completed Phase IB/IIA trial of AT-527 in treatment-naïve HCV-infected patients, including HCV-infected patients with Child-Pugh A (CPA) cirrhosis. The data will be presented on November 10, 2018 at The Liver Meeting^® 2018 sponsored by the American Association for the Study of Liver Diseases taking place in San Francisco, California.   

• Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update

  08 November 2018

  

  Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended  September 30, 2018  and provided an update on its development programs.

• Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update

  05 November 2018

  

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced it will provide an update on E2112, its NCI-sponsored, ECOG-ACRIN led pivotal trial of entinostat plus exemestane in hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) breast cancer as well as its registration strategy for entinostat in combination with KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC).

• Presentation of Additional Analyses of Clearside’s PEACHTREE Clinical Trial Data Further Supports Potential of XIPERE™ in Treating Uveitic Macular Edema

  29 October 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that additional  data from PEACHTREE, the company’s pivotal Phase 3 trial of XIPERE™ (formerly “suprachoroidal CLS-TA”) in patients with uveitic macular edema, were presented at the  American Academy of Ophthalmology  (“AAO”) 2018 Annual Meeting by  Rahul N. Khurana , MD, Vitreoretinal Surgeon at  Northern California Retina Vitreous Associates , Clinical Associate Professor in Ophthalmology at  UCSF Medical Center , and a Principal Investigator for PEACHTREE. 

• Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer, Effective December 10

  29 October 2018

  

  Epic Sciences, Inc. (Epic) and Genomic Health, Inc. (Nasdaq: GHDX) announced today that Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, has issued a positive final local coverage determination (LCD) for the Oncotype DX® AR-V7 Nucleus Detect™ test. The final LCD recommends Medicare coverage for use of the test effective December 10, 2018, throughout the United States to help determine which patients with metastatic castrate resistant prostate cancer (mCRPC) may benefit from continued androgen receptor signaling inhibitor (ARSi) therapy, such as enzalutamide, abiraterone and apalutamide, as well as those who are resistant who may benefit from chemotherapy.

• Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results

  29 October 2018

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the third quarter ended September 30, 2018.